Taiko Pharmaceutical
Basic Information
- Stock Code
- 4574
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- November 1946
- Listing Year
- March 2009
- Official Website
- https://www.seirogan.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Gurunavi, Rohto Pharmaceutical, Disrupta, DM Mix
Overview
Taiko Pharmaceutical is a pharmaceutical manufacturer founded in 1946, renowned for its high recognition in the production and sales of over-the-counter drugs centered on Seirogan and chlorine dioxide disinfectant and deodorant products.
Current Situation
Taiko Pharmaceutical recorded consolidated sales of approximately 5 billion yen for the fiscal year ended December 2022, but operating profit and net profit were significantly in the red. Its flagship product Seirogan holds about 90% market share in the domestic market and provides stable revenue, but administrative fines and litigation issues stemming from violations of the Premiums and Representations Act regarding chlorine dioxide-related products have impacted management. Although aiming to expand its infection control business, there is social criticism regarding the scientific basis of the products, posing risks to brand image. It is strengthening its management base through a capital and business alliance with Earth Corporation and considering consolidating production sites in the Kansai Science City. In the future, it plans to focus on developing products with clear safety and efficacy, as well as strengthening digital marketing, to pursue mid- to long-term growth strategies.
Trivia
Interesting Facts
- Seirogan holds approx. 90% sales share in the domestic market.
- The trumpet mark originates from the melody of the old army signal trumpet.
- Paid the highest-ever surcharge for Premiums and Representations Act violation on Krevlin products.
- Founder Otujiro Shibata established Shibata Seiyakusho in 1940.
- Entered capital and business alliance with Earth Corporation, becoming its third-largest shareholder.
- Considering integration of Suita factory production site into Kansai Science City.
- Seirogan is a traditional gastrointestinal drug with over 100 years of history.
- Chlorine dioxide products have been deployed as infection control business since 2006.
- Trumpet melody has been used for over 60 years since private broadcasting started in 1951.
- 'Krev & And' launched in 2019 as a derivative brand of Krevlin.
- Announced voluntary retirement program following Consumer Affairs Agency order.
- Head office located in Orix Honmachi Building, Osaka City.
- 'Pishat' is an OD tablet-type antidiarrheal.
- CM features celebrities like Kenjiro Ishimaru and Kaori Minamide.
- Technical alliance with Korea's Dongseong Pharmaceutical since 1972.
Hidden Connections
- The trumpet mark on Seirogan is inspired by the old Imperial Japanese Army signal trumpet.
- Business alliance with Earth Corporation strengthens product development and distribution network.
- Patented chlorine dioxide technology serves as a key differentiator against competitors.
- Shareholder representative litigation has impacted even top management's asset formation.
- Factory relocation plan to Kansai Science City aims for R&D consolidation.
- Local ties with Kyocera Dome Osaka for behind-the-scenes net advertising.
- Long-term technical exchange with Korea's Dongseong Pharmaceutical as sister company.
- Seirogan's main ingredient wood creosote differentiates as a natural component.
Future Outlook
Growth Drivers
- Increased demand for disinfectant products due to rising infection control needs
- Expansion of OTC drug market amid aging society
- Enhanced sales power through strengthened alliance with Earth Corporation
- Progress in new product development leveraging patented technology
- Expansion of online marketing and EC sales
- Strengthened market trust in products with proven safety and efficacy
- Cost reductions via factory consolidation and logistics efficiency
- Sales diversification through overseas market entry
- Improved consumer loyalty via brand revitalization
- Technology investments in digital health field
Strategic Goals
- Clarify scientific basis of chlorine dioxide disinfectant products and restore trust
- Maintain over 90% share in domestic OTC drug market
- Deploy over 10 regional community contribution activities annually
- Achieve 30% reduction in environmental impact through energy-efficient manufacturing sites
- Execute growth strategy to increase sales to approx. ¥8 billion
- Further deepen strategic alliance with Earth Corporation
- Expand online sales ratio to over 20% of total
- Expand product lineup through development and launch of diverse new products
- Promote employee diversity and create better workplace environment
- Strengthen brand through development of products with superior safety and efficacy
Business Segments
Infection Control Business
- Overview
- Provides disinfectant and deodorant products using low-concentration chlorine dioxide technology and deploys hygiene solutions.
- Competitiveness
- Patented technology enables long-term maintenance of stable chlorine dioxide concentrations.
- Customers
-
- Hospitals and Medical Institutions
- Nursing Homes
- Public Facilities
- Restaurants
- Educational Institutions
- Corporate Facilities
- Transportation Companies
- Retail Stores
- Hotels and Accommodations
- Manufacturing
- Products
-
- Chlorine Dioxide Gas Disinfectant Products
- Krevlin Series
- Disinfectant and Deodorizer Devices
- Hygiene Management Solutions
Over-the-Counter Drug Wholesale
- Overview
- Established a stable supply system for over-the-counter drugs to retailers nationwide.
- Competitiveness
- Strong wholesale network backed by high brand recognition.
- Customers
-
- Drugstore Chains
- Pharmacies and Drugstores
- Mail-Order Retailers
- Retailers
- Medical Institutions
- Products
-
- Seirogan Series
- Various Gastrointestinal and Intestine Regulators
- General Quasi-Drugs
License Sales
- Overview
- Deploys product supply and brand licensing for overseas markets.
- Competitiveness
- Leverages the historical brand value of Seirogan.
- Customers
-
- Overseas Pharmaceutical Manufacturers
- Local Sales Agents
- Products
-
- Seirogan Branded Products
- Chlorine Dioxide Products
Competitive Advantage
Strengths
- Overwhelming brand recognition of Seirogan
- Long years of pharmaceutical manufacturing technology
- Proprietary chlorine dioxide technology
- Capital and business alliance with Earth Corporation
- Diverse sales channel deployment
- Solid manufacturing and R&D base
- Local community trust
- Sales networks domestically and internationally
- Diversified product lineup
- Historic logo and marketing strength
- Employee expertise and experience
- Technology leveraging strong patents
- Competitive protection through intellectual property
- High customer loyalty
- Long-term market share maintenance
Competitive Advantages
- Secured approx. 90% domestic market share centered on Seirogan
- Differentiation from competitors via patented chlorine dioxide products
- Strengthened product development through alliance with Earth Corporation
- Broad response to consumer needs with diverse product range
- High distribution power through nationwide sales channels
- Brand reliability based on over 120 years of history
- Low-cost structure via optimized inventory management and production efficiency
- Strong brand image from 'Trumpet Mark' logo
- Established appropriate quality control and regulatory compliance
- Strengthened market base through good relations with local communities
- Resilience to environmental changes via proprietary technology
- Potential for market expansion through new product launches
- Increased awareness via advertising and media strategies
- Market share growth through product lineup diversification
- Prevents competitor entry with strong legal patent protection
Threats
- Impact of administrative sanctions from Premiums and Representations Act violations
- Competitors' pharmaceutical technology innovations
- Demand fluctuations from changing consumer health awareness
- Lack of brand recognition in overseas markets
- Risk of imitation of patented technology
- Tightening regulations or changes in drug regulations
- Social criticism on product safety
- Market volatility from new infectious diseases and uncertainties
- Impact from changes in sales channels
- Influence of exchange rate fluctuations on overseas expansion
- Raw material price fluctuation risks
- Potential deterioration of corporate image from shareholder lawsuits
Innovations
2022: Improvement and Development of Chlorine Dioxide Disinfectant Products
- Overview
- Developed and launched products with enhanced sustained disinfection effects using patented technology for long-term chlorine dioxide gas concentration retention.
- Impact
- Achieved extended product life and increased customer satisfaction
2021: Launch of Seirogan Quick C
- Overview
- Developed and market-launched liquid capsule-type gastrointestinal drug aiming for rapid effect onset.
- Impact
- Expanded new customer base and product lineup
2020: Strengthening Hygiene Solutions for Infection Control
- Overview
- Enhanced functionality of chlorine dioxide product lineup for medical and nursing facilities, expanding hygiene management proposals.
- Impact
- Improved competitiveness and business expansion in B2B market
Sustainability
- Efforts to reduce environmental impact of chlorine dioxide products
- Infection prevention awareness activities in collaboration with local communities
- Manufacturing process improvements for energy efficiency
- Strengthening legal compliance and quality assurance systems
- Internal initiatives for employee health and safety
- Raising awareness for sustainable resource use
- Introduction of environmentally considerate product packaging design
- Logistics efficiency via digital utilization
- Promotion of green procurement
- Implementation of waste reduction programs
- Ensuring transparency through external audits
- Initiatives to promote diversity and inclusion